Results 231 to 240 of about 123,268 (305)

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo   +10 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou   +2 more
wiley   +1 more source

Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 (ABCB1) and ATP‐binding cassette super‐family G member 2 (ABCG2) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin ...
Hoang Dat Nguyen   +4 more
wiley   +1 more source

Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation. [PDF]

open access: yesJ Antimicrob Chemother
Morales Junior R   +11 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Clinical science and care incorporating the development of a European Platform for Clinical Research in Diabetes (EPCRD) [PDF]

open access: yes, 2010
Danne, T.   +8 more
core  

Home - About - Disclaimer - Privacy